These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19031015)

  • 1. Stroke due to doxorubicin-induced cardiac toxicity.
    Kara G; Taşoğlu O; Dizdar O; Altundağ K; Ozçakar L
    Med Oncol; 2009 Dec; 26(4):506-7. PubMed ID: 19031015
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin cardiotoxicity in the elderly: old drugs and new opportunities.
    Carver JR; Schuster SJ; Glick JH
    J Clin Oncol; 2008 Jul; 26(19):3122-4. PubMed ID: 18591552
    [No Abstract]   [Full Text] [Related]  

  • 3. Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy.
    Blaes AH; Rehman A; Vock DM; Luo X; Menge M; Yee D; Missov E; Duprez D
    Vasc Health Risk Manag; 2015; 11():591-4. PubMed ID: 26648730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum carnitine levels during the doxorubicin therapy. Its role in cardiotoxicity.
    Yaris N; Ceviz N; Coskun T; Akytüz C; Büyükpamukçu M
    J Exp Clin Cancer Res; 2002 Jun; 21(2):165-70. PubMed ID: 12148572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy.
    Sipola P; Vanninen E; Jantunen E; Nousiainen T; Kiviniemi M; Hartikainen J; Kuittinen T
    Nucl Med Commun; 2012 Jan; 33(1):51-9. PubMed ID: 22044862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early heart transplant in a child with advanced lymphoma.
    Morgan E; Pahl E
    Pediatr Transplant; 2002 Dec; 6(6):509-12. PubMed ID: 12453205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How could we solve the diagnostic dilemma of doxorubicin toxicity in high-risk patients?
    Davutoglu V; Soydinc S; Akdemir I
    J Natl Med Assoc; 2004 May; 96(5):689-90. PubMed ID: 15160987
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiac toxicity of daunorubicin.
    Bonadonna G; Monfardini S
    Lancet; 1969 Apr; 1(7599):837. PubMed ID: 4180385
    [No Abstract]   [Full Text] [Related]  

  • 9. [Doxorubicin-induced cardiotoxicity: are there effective alternatives for prevention?].
    Canales MA
    Med Clin (Barc); 2010 Jan; 134(2):70-1. PubMed ID: 19896152
    [No Abstract]   [Full Text] [Related]  

  • 10. Adriamycin cardiac toxicity: a different hypothesis.
    Byfield JE
    Cancer Treat Rep; 1977; 61(3):497-8. PubMed ID: 872149
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiotoxicity of doxorubicin and other anthracycline derivatives.
    Jain D
    J Nucl Cardiol; 2000; 7(1):53-62. PubMed ID: 10698235
    [No Abstract]   [Full Text] [Related]  

  • 12. Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.
    Simsir SA; Lin SS; Blue LJ; Gockerman JP; Russell SD; Milano CA
    Ann Thorac Surg; 2005 Aug; 80(2):717-9. PubMed ID: 16039240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery from anthracycline cardiomyopathy--how can it be explained?
    Christiansen S
    J Heart Lung Transplant; 2009 Jul; 28(7):751. PubMed ID: 19560709
    [No Abstract]   [Full Text] [Related]  

  • 14. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
    Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
    Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors.
    Schmitt CJ; Dietrich S; Ho AD; Witzens-Harig M
    Ann Hematol; 2012 Mar; 91(3):391-7. PubMed ID: 21850390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
    Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
    J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individualized liposomal doxorubicin-based treatment in elderly patients with non-Hodgkin's lymphoma.
    Guo B; Zhu HL; Li SX; Lu XC; Fan H
    Onkologie; 2011; 34(4):184-8. PubMed ID: 21447976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective monitoring for anthracycline cardiotoxicity: an introduction.
    McGuire WP
    Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased risk of cardiac dysfunction after anthracyclines in girls.
    Silber JH; Jakacki RI; Larsen RL; Goldwein JW; Barber G
    Med Pediatr Oncol; 1993; 21(7):477-9. PubMed ID: 8341214
    [No Abstract]   [Full Text] [Related]  

  • 20. Curing the cure: utilizing exercise to limit cardiotoxicity.
    Emter CA; Bowles DK
    Med Sci Sports Exerc; 2008 May; 40(5):806-7. PubMed ID: 18408620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.